Prevention of coronary heart disease in women

doi:10.1017/CBO9780511545672.012

12 - Prevention of coronary heart disease in women

from Part III - Disease prevention

Published online by Cambridge University Press: 21 August 2009

Valerie K Ulstad

Edited by

Jo Ann Rosenfeld

Show author details

Valerie K Ulstad: Affiliation:
West Hennepin County Medical Center, Minneapolis, MN, USA
Jo Ann Rosenfeld: Affiliation:
The Johns Hopkins University

Book contents

Get access

Summary

Case 1: a 62-year-old woman comes to you as a new patient. She has no complaints but needs preventive care. She smokes one pack of cigarettes per day and is on no medications. She does no regular physical exercise and has a desk job. She has no chronic medical problems. Her blood pressure is 150/90mmHg, and she has a body mass index (BMI) of 38kg/m2 and a waist-to-hip ratio of 1.2. There are no other physical exam abnormalities. You order fasting screening labs, which show total cholesterol of 265mg/dl (6.9 mmol/l), low-density lipoprotein (LDL) 180mg/dl (4.7mmol/l), high-density lipoprotein (HDL) 25mg/dl (0.65mmol/l), triglycerides 300mg/dl (3.4mmol/l), and glucose 180mg/dl.

Case 2: a 65-year-old woman presents for new patient evaluation after a recent hospitalization for an inferior myocardial infarction (MI). She was treated acutely with angioplasty and stent placement in the right coronary artery. She also has a 30% left anterior descending coronary artery lesion and a 20% circumflex lesion. Her ejection fraction is 40%. She has had no further angina and denies symptoms of congestive heart failure. She smokes half a pack of cigarettes per day and proudly tells you this is much less than she used to smoke. She has no other chronic medical problems.

She is taking atenolol, aspirin, and atorvastatin. Her blood pressure is 160/100mmHg, pulse is 90bpm, BMI is 35kg/m2, and the reminder of her examination is unremarkable. In hospital, her cholesterol was 330mg/dl (8.5mmol/l), LDL 190mg/dl (4.9mmol/l), HDL 40 mg/dl (1.0mmol/l), triglycerides 500mg/dl (5.6mmol/l), and hemoglobin A1C 6.0%.[…]

Keywords

angiotensin-converting enzyme inhibitors antiplatelet therapy atherosclerosis beta-blockers diabetes coronary heart disease LDL cholesterol cardiovascular disease low HDL cholesterol physical inactivity

Type: Chapter
Information: Women's Health in Mid-Life
A Primary Care Guide
, pp. 209 - 224

DOI: https://doi.org/10.1017/CBO9780511545672.012 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2001

European Heart Network. www.ehnheart.org/statistics/summary. Accessed September 23, 2002

Verma, S. and Anderson, T. J.Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105:546–9CrossRef Google Scholar PubMed

Lerner, D. J. and Kannel, W. B.Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am. Heart J. 1986; 111:383–90CrossRef Google Scholar PubMed

Rich-Edwards, J. W., Manson, J. E., Hennekens, C. H and Buring, J. E.The primary prevention of coronary heart disease in women. N. Engl. J. Med. 1995; 332: 1758–66CrossRef Google Scholar PubMed

Grundy, S. M., Pasternak, R., Greenland, P., et al.Assessment of cardiovascular risk by use of multiple risk factor equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J. Am. Coll. Cardiol. 1999; 34:1348–59CrossRef Google Scholar PubMed

Wilson, P. W. F., D'Agostino, R. B., Levy, D., et al.Prediction of coronary risks using risk factor categories. Circulation 1998; 97:1837–47CrossRef Google Scholar PubMed

www.statcoder.com. Accessed September 23, 2002

www.nhlbi.nih.gov/health/public/heart/other/hhw/index.htm. Accessed September 23, 2002

Willett, W. C., Green, A., Stampfer, M. J., et al.Relative and absolute excess risk of coronary heart disease among women who smoke cigarettes. N. Engl. J. Med. 1987; 317:1303–9CrossRef Google Scholar PubMed

Ockene, I. S. and Miller, N. H.Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:3243–7CrossRef Google Scholar PubMed

Mosca, L., Grundy, S., Judelson, D., et al.Guide to preventive cardiology for women. AHA/ACC Scientific statement: consensus panel statement. J. Am. Coll. Cardiol. 1999; 33:1751–5Google Scholar PubMed

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 1997; 157:2413–46CrossRef

Moser, M., Hebert, P. and Hennekens, C. H.An overview of the meta-analyses of the hypertension treatment trials. Arch. Intern. Med. 1991; 151:1277–9CrossRef Google Scholar PubMed

Labarthe, D. and Ayala, C.Non-drug interventions in hypertension prevention and control. Cardiol. Clin. 2002; 20:249–63CrossRef Google Scholar

Grundy, S. M., Howard, B., Smith, S., et al.Prevention conference VI: diabetes and cardiovascular disease. Executive summary. Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105:2231–9CrossRef Google Scholar PubMed

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001; 285:2486–97CrossRef

Ford, E. S., Giles, W. H. and Dietz, W. H.Prevalence of the metabolic syndrome among U.S. adults: findings from the third National Health and Nutrition Survey. J. Am. Med. Assoc. 2002; 287:356–9CrossRef Google Scholar

Lemaitre, R. N., Psaty, B. M., Heckbert, S. R., et al.Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults – evidence from the cardiovascular health study. Arch. Intern. Med. 2002; 162:1395–400CrossRef Google Scholar PubMed

Downs, J. R., Clearfield, M., Weis, S., et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex CAPS. J. Am. Med. Assoc. 1998; 279:1615–22CrossRef Google Scholar

Sacks, F. M., Pfeffer, M. A., Moye, L. A., et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N. Engl. J. Med. 1996; 335:1001–9CrossRef Google Scholar PubMed

Packard, C. J.Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 87: 1440–45Google Scholar

LaRosa, J. C., He, J. and Vupputuri, S.Effect of statins on the risk of coronary disease: a meta-analysis of randomized controlled trials. J. Am. Med. Assoc. 1999; 282:2340–46CrossRef Google Scholar PubMed

Yeung, A. C. and Tsao, P.Statin therapy: beyond cholesterol lowering and anti-inflammatory effects. Circulation 2002; 105:2937–38CrossRef Google Scholar

Pasternak, R. C., Smith, S. C. Jr, Bairey-Merz, C. N., et al.ACC/AHA/NHLBI advisory on the use and safety of statins. J. Am. Coll. Cardiol. 2002; 40:567–72CrossRef Google Scholar PubMed

Field, A. E., Coakley, E. H., Must, A., et al.Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch. Intern. Med. 2001; 161:1581–6CrossRef Google Scholar PubMed

Manson, J. E., Stampfer, M. J., Colditz, G. A., et al.A prospective study of obesity and the risk of coronary heart disease in women. N. Engl. J. Med. 1990; 322:882–9CrossRef Google Scholar PubMed

Eckel, R. H.Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997; 96:3248–50CrossRef Google Scholar PubMed

Bjorntorp, P.Regional patterns of fat distribution. Ann. Intern. Med. 1985; 103: 994–5CrossRef Google Scholar PubMed

Lemaitre, R. N., Heckbert, S. R., Psaty, B. M. and Siscovick, D. S.Leisure-time physical activity and the risk of nonfatal myocardial infarction in postmenopausal women. Arch. Intern. Med. 1995; 155:2302–8CrossRef Google Scholar PubMed

Kushi, L. H., Fee, R. M., Folsom, A. R., et al.Physical activity and mortality in postmenopausal women. J. Am. Med. Assoc. 1997; 277:1287–92CrossRef Google Scholar PubMed

Fletcher, G. F., Balady, G., Blair, S. N., et al.Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for healthcare professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996; 94:857–62CrossRef Google Scholar

Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. J. Am. Med. Assoc. 1996; 276:241–6CrossRef

US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, National Center for Chronic Disease Prevention and Health Promotion; 1996

Manson, J. E., Stampfer, M. J., Colditz, G. A., et al.A prospective study of aspirin use and primary prevention of cardiovascular disease in women. J. Am. Med. Assoc. 1991; 266:521–7CrossRef Google Scholar PubMed

US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann. Intern. Med. 2002; 136:157–60CrossRef

Lauer, M.Aspirin for the primary prevention of coronary events. N. Engl. J. Med. 2002; 346:1468–74Google Scholar PubMed

Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 1994; 308:81–106CrossRef

Hennekens, C. H., Dyken, M. L. and Fuster, V.Aspirin as a therapeutic agent in cardiovascular disease. A statement for health care professionals from the American Heart Association. Circulation 1997; 96:2751–3CrossRef Google Scholar

Smith, S. C., Blair, S. N., Bonow, R. O., et al.AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001; 104:1577–9CrossRef Google Scholar PubMed

Frishman, W. H. and Cheng, A.Secondary prevention of myocardial infarction: role of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors. Am. Heart J. 1999; 137:S25–34CrossRef Google Scholar PubMed

Gheorghiade, M. and Golstein, S.Beta blockers in the post-myocardial infarction patient. Circulation 2002; 106: 394–8CrossRef Google Scholar PubMed

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344:1383–9

Lewis, S. J., Sacks, F. M., Mitchell, J. S., et al.Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J. Am. Coll. Cardiol. 1998; 32:140–46CrossRef Google Scholar PubMed

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998; 339:1349–57CrossRef

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7–22CrossRef

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342:145–53CrossRef

Yusuf, S.Two decades of progress in preventing vascular disease. Lancet 2002; 360:2–3CrossRef Google Scholar PubMed

American College of Cardiology and American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with acute myocardial infarction. www.acc.org/clinical/guidelines/nov96/1999/index.htm. Accessed September 23, 2002

Mosca, L., Manson, J. E., Sutherland, S. E., et al.Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:2468–82CrossRef Google Scholar PubMed

DeLorgeril, M., Salen, P., Martin, J. L., et al.Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99:779–85CrossRef Google Scholar

American Heart Association. www.americanheart.org. Accessed September 23, 2002

Boushey, C. J., Beresford, S. A. A., Omenn, G. S. and Motulsky, A. G.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease; probable benefits of increasing folic acid intakes. J. Am. Med. Assoc. 1995; 274:1049–57CrossRef Google Scholar PubMed

Nygard, O., Nordrehaug, J. E., Refsum, H., et al.Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 1997; 337:230–36CrossRef Google Scholar PubMed

Malinow, M. R., Bostom, A. G., Krauss, R. M.Homocysteine, diet and cardiovascular diseases: a statement for health care professionals from the nutrition committee, American Heart Association. Circulation 1999; 99:178–82CrossRef Google Scholar

Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br. Med. J. 1998; 316:894–8CrossRef

Schnyder, G., Roffi, M., Flammer, Y., Pin, R. and Hess, O. M.Effect of homocysteine-lowering therapy with folic acid, vitamin B 12, and vitamin B 6 on clinical outcomes after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. J. Am. Med. Assoc. 2002; 288:973–9CrossRef Google Scholar

Grady, D., Herrington, D., Bittner, V., et al.Cardiovascular disease outcomes during 6.8 years of hormone replacement therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). J. Am. Med. Assoc. 2002; 288:49–57CrossRef Google Scholar

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results form the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 2002; 288:321–33CrossRef

Book contents

12 - Prevention of coronary heart disease in women

Summary

Keywords

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive